Core Alternative Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$364K Buy
2,442
+253
+12% +$35.5K 0.11% 96
2026
Q2
$277K Buy
2,189
+319
+17% +$42K 0.08% 101
2026
Q1
$261K Buy
1,870
+286
+18% +$40K 0.08% 103
2025
Q4
$194K Buy
1,584
+1,278
+418% +$155K 0.05% 112
2025
Q3
$34K Hold
306
– – 0.01% 144
2025
Q2
$33.9K Hold
306
– – 0.01% 146
2025
Q1
$34.3K Buy
306
+241
+371% +$24.9K 0.01% 146
2024
Q4
$6K Hold
65
– – ﹤0.01% 223
2024
Q3
$5.45K Hold
65
– – ﹤0.01% 226
2024
Q2
$4.46K Hold
65
– – ﹤0.01% 231
2024
Q1
$4.76K Sell
65
-564
-90% -$43.4K ﹤0.01% 223
2023
Q4
$51K Sell
629
-867
-58% -$67.5K 0.01% 167
2023
Q3
$112K Sell
1,496
-24
-2% -$1.85K 0.02% 137
2023
Q2
$117K Buy
1,520
+243
+19% +$19.4K 0.02% 114
2023
Q1
$106K Sell
1,277
-1,100
-46% -$91.1K 0.01% 111
2022
Q4
$204K Buy
2,377
+73
+3% +$5.78K 0.03% 98
2022
Q3
$142K Buy
2,304
+184
+9% +$11.6K 0.02% 100
2022
Q2
$131K Buy
2,120
+170
+9% +$10.5K 0.03% 108
2022
Q1
$116K Buy
1,950
+783
+67% +$50.1K 0.03% 109
2021
Q4
$85K Buy
+1,167
New +$80.4K 0.02% 108

Other funds holding GILD

Core Alternative Capital's GILD Position: Q3 2026 in Review

Core Alternative Capital increased its Gilead Sciences (GILD) stake by 12% in Q3 2026, buying an estimated $35.5K and bringing the position to 2,442 shares worth $364K. The position accounts for 0.11% of the portfolio, ranked #96.

Core Alternative Capital first reported a position in GILD in Q4 2021 and has held it in 20 quarters since. 2,357 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Core Alternative Capital held 2,442 shares of Gilead Sciences worth $364K as of Q3 2026.
  • Core Alternative Capital bought 253 Gilead Sciences shares in Q3 2026, an estimated $35.5K.
  • Gilead Sciences made up 0.11% of Core Alternative Capital's portfolio in Q3 2026, its #96 holding.
  • Core Alternative Capital first reported a position in Gilead Sciences in Q4 2021 and has held it in 20 quarters since.
  • 2,357 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Core Alternative Capital's 13F filing for Q3 2026, filed 12 Nov 2026.